(Q72855200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

title

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference

1 reference

F Capra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

M Casaril

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

G B Gabrielli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

P Tognella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

A Rizzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

L Dolci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

R Colombari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

P Mezzelani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

R Corrocher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

G De Sandre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 April 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

112-118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

Interferons and their actions

29 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Interferon therapy for chronic type B hepatitis: the promise comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Beta- and gamma-interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Hepatic fibrosis and its serum markers: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Hepatic fibrosis--new therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Hepatic fibrosis and collapse: histological distinction by orcein staining

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Non-A, Non-B hepatitis: sorting through a diagnosis of exclusion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Histological improvement after anti-viral treatment for chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980018-2

7 January 2021

10.1016/S0168-8278(05)80018-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8340603%20AND%20SRC:MED&resulttype=core&format=json